Interview with Frederic Dufour, General Manager, Biocodex Russia
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
Address: 119019, г. Москва, ул. Новый Арбат д. 21,Russia
Tel: +7 (495) 783-26-80
Biocodex is an independent, family-owned French pharmaceutical company founded in 1953 by Michel Hublot and Francois Vallet.
We are present in more than 100 countries of the world through subsidiaries and partner companies.
We specialize in several therapeutic areas, namely:
– gastroenterology;
– neurology and psychiatry;
– pain treatment.
Our mission: to develop and make accessible to doctors and their patients effective and safe products which improve the health and quality of life of patients.
Biocodex in Russia
Biocodex drugs have been present in Russia since 1996.
In July 2008 the Biocodex company opened its representative office in Russia with head office in Moscow and 14 major cities covered.
Since 2009 the company promotes pharmaceuticals of a French ophthalmic company Laboratoires Thea, a European leader in the sphere of ophthalmology.
We specialize in several therapeutic areas, namely:
– gastroenterology;
– neurology and psychiatry;
– pain treatment.
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
Valenta was established in 1997 as Otechestvennye Lekarstva, and today represents the consolidation of several facilities and business holding groups. Can you give our readers an overview of the company’s…
Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been…
Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your…
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Ferring is a specialty biopharmaceutical company that operates in four strategic therapeutic areas. Globally, many pharma companies have been diversifying their portfolio, and entering the OTC segment, generics segment, medical…
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
The AEB works through a number of channels to promote the interests of European corporations with operations in Russia. It has a long history in this country, dating back to…
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this plant, both for the…
Many expat managers have used Russia as a stepping-stone, but you have headed this business for an astounding 9 years. What is it about this country and about Reckitt Benckiser’s…
See our Cookie Privacy Policy Here